Drug Discovery World

AUGUST 31, 2023

HBCI was established as a subsidiary of HBC earlier this year, with a focus on the discovery and development of peptides that normalise tumour micro-environments, resulting in the improved performance of immunotherapies and chemotherapies. Other potential cancer indications with ongoing in vitro work include breast and ovarian cancer.

Gene Expression 52

Gene Expression Gene In-Vitro Research 52

Pharmaceutical Technology

MAY 4, 2023

The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results. This cohort showed a safety profile identical to that found in older children and adults.

In-Vitro 246

In-Vitro Genetic Disease Medicine Genetics 246

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

MAY 12, 2023

Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Scienmag

DECEMBER 10, 2020

Credit: Nucleic Acids Research Scientists at Tokyo Institute of Technology decipher how to quantitatively assess the effects of specific epigenetic changes on the rate of transcription by developing a mathematical model. For this, they successfully generated reconstituted chromatin bearing histone modifications in vitro.

Gene Expression 52

Gene Expression In-Vitro Gene Scientist 52

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Pharmaceutical Technology

MAY 24, 2023

Our board and management team believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What data did you present at the conference?

RNA 65

RNA In-Vivo In-Vitro DNA 65

FDA Law Blog

MARCH 31, 2024

They believe any regulatory oversight for laboratory developed tests (LDTs) should be mandated by Congress, rather than the Executive Branch. The majority of witnesses, along with several of the Congressional members, agreed that legislation is the appropriate path to regulating laboratory developed tests.

Regulation 64

Regulation In-Vitro Development Gene Therapy 64

Drug Discovery World

JANUARY 17, 2024

Scientists from Fujita Health University have shown that mitochondria play essential roles during muscle development, regeneration and maintenance. The results were consistent with the in vitro experiments. Thus, problems with mitochondria can immediately translate to muscle diseases, including muscle atrophy.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS. The post Could CRISPR cure HIV?

Gene Editing 106

Gene Editing In-Vivo DNA In-Vitro 106

Drug Discovery World

FEBRUARY 6, 2024

She speaks to Megan Thomas on how genomics can advance drug discovery and development. She speaks to Megan Thomas on how genomics can advance drug discovery and development. In vitro and in silico models are becoming increasingly sophisticated in predicting drug safety profiles and preventing costly and time-consuming clinical trials.

Genome 59

Genome Genomics Genetics In-Vitro 59

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Bioengineer

JANUARY 16, 2024

Often, the loss of T790M is associated with the development of alternative competitive resistance mechanisms. In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. months vs. 15.2 months, p = 0.01).

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. They are different from small molecules in terms of their size and complexity.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

Drug Discovery World

OCTOBER 27, 2023

Accurate modeling of the human tumour microenvironment is essential to the development of new cancer therapies, but has always been a challenge for drug developers. Accurate modeling of the human tumour microenvironment is essential to the development of new cancer therapies, but has always been a challenge for drug developers.

Research 73

Research Gene Therapy In-Vivo In-Vitro 73

pharmaphorum

NOVEMBER 1, 2022

We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA. Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 105

DNA In-Vitro Doctors Doctor 105

STAT News

FEBRUARY 23, 2023

Now, a growing chorus of physicians is recommending a procedure that can significantly reduce the chances of developing ovarian cancer. No tests are available to detect it early, so most patients are diagnosed in later stages, when the cancer is more likely to have spread. The group is not alone in promoting the strategy.

Genetics 111

Genetics In-Vitro Research Gene 111

Drug Discovery World

FEBRUARY 9, 2024

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. Chris explained that DefiniGEN is a liver cell company focussed on hepatocytes, particularly supporting the drug development industry in producing liver therapies.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52

Delveinsight

JANUARY 12, 2021

Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. AvantGen has announced the licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. R on macrophages.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Drug Discovery World

JANUARY 12, 2023

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. . The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Gene and cellular therapies. These products can be derived from humans, animals, or microorganisms with biotechnology.

Development 180

Development Protein Production Hormones 180

The Pharma Data

DECEMBER 20, 2020

Athenex and Almirall have a license deal with Almirall having the license to research, develop and commercialize the drug in the U.S. Klisyri is a home-grown product discovered and characterized by Athenex scientists and developed from pre-IND to NDA by the Athenex team. The drug is a once-daily, beta-3 adrenergic agonist.

In-Vitro 52

In-Vitro FDA Approval Manufacturing Licensing 52

XTalks

APRIL 13, 2021

While it has been known for about five decades now that patients with Parkinson’s disease have a higher likelihood of developing melanoma than the general population, the exact reasons for this were unknown. Now, thanks to a study funded by the National Institutes of Health Intramural Research Program, scientists have discovered that ?-synuclein,

Research 98

Research Protein In-Vitro Gene Therapy 98

The Pharma Data

MAY 31, 2022

Of the babies with 2 or 3 copies of the SMN2 gene (n=6), 100% were able to sit after one year of treatment with Evrysdi, 67% could stand and 50% of infants could walk independently. . Roche’s Chief Medical Officer and Head of Global Product Development. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Organoids are developed using pluripotent stem cells (PSCs) or adult stem cells in a 3D culture matrix, and mimic organs in the human body. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

NOVEMBER 29, 2021

About LENVIMA ® (lenvatinib); available as 10 mg and 4 mg capsules LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase asset that inhibits the kinase conditioning of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).

In-Vitro 52

In-Vitro Containment Development Medicine 52

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

XTalks

SEPTEMBER 30, 2020

In collaboration with clinicians around the world, Casanova’s team studied the genomes of COVID-19 patients, focusing on a set of 13 genes involved in interferon immunity against influenza. The findings reveal a critical role for IFNs in fighting COVID-19 infection, positioning them to be a potential therapeutic target in the disease.

Antibody 135

Antibody Genetics Research In-Vitro 135